Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan

Journal of Clinical Oncology

Volumn 26, Issue 2, 2008, Pages 271-278

  Sathornsumetee, Sith ^a   Cao, Yiting ^a   Marcello, Jennifer E ^a   Herndon II, James E ^a   McLendon, Roger E ^a   Desjardins, Annick ^a   Friedman, Henry S ^a   Dewhirst, Mark W ^a   Vredenburgh, James J ^a   Rich, Jeremy N ^a  

^a DUKE CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBONATE DEHYDRATASE IX; CD31 ANTIGEN; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 2ALPHA; IRINOTECAN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

AGED; ANGIOGENESIS; ARTICLE; ASTROCYTOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; FEMALE; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOXIC CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENT CANCER; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; THERAPY EFFECT; TISSUE SECTION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANOXIA; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASTROCYTOMA; BRAIN NEOPLASMS; CAMPTOTHECIN; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 38349155463     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.13.3652     Document Type: Article

References (33)

1. Jain RK, di Tomaso E, Duda DG, et al: Angiogenesis in brain tumours. Nat Rev Neurosci 8:610-622, 2007
2. Vredenburgh JJ, Desjardins A, Herndon JE II, et al: Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13:1253-1259, 2007
3. Vredenburgh JJ, Desjardins A, Herndon JE II, et al: Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.J Clin Oncol25:4722-729, 2007
4. Jubb AM, Oates AJ, Holden S, et al: Predicting benefit from anti-angiogenic agents in malignancy. Nat Rev Cancer 6:626-635, 2006
5. Haas-Kogan DA, Prados MD, Tihan T, et al: Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 97:880-887, 2005
6. Mellinghoff IK, Wang MY, Vivanco I, et al: Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353:2012-2024, 2005
7. Pouysségur J, Dayan F, Mazure NM: Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441:437-443, 2006
8. Kaur B, Khwaja FW, Severson EA, et al: Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro Oncol 7:134-153, 2005
9. Haapasalo JA, Nordfors KM, Hilvo M, et al: Expression of carbonic anhydrase IX in astrocytic tumors predicts poor prognosis. Clin Cancer Res 12:473-477, 2006
10. Korkolopoulou P, Perdiki M, Thymara I, et al: Expression of hypoxia-related tissue factors in astrocytic gliomas: A multivariate survival study with emphasis upon carbonic anhydrase IX. Hum Pathol 38:629-638, 2007
11. Potter C, Harris AL: Hypoxia inducible carbonic anhydrase IX, marker of tumour hypoxia, survival pathway and therapy target. Cell Cycle 3:164-167, 2004
12. Sowter HM, Raval R, Moore J, et al: Predominant role of hypoxia inducible transcription factor Hif-1α versus Hif-2α in regulation of the transcriptional response to hypoxia. Cancer Res 63:6130-6134, 2003
13. Hu CJ, Wang LY, Chodosh LA, et al: Differential roles of hypoxia inducible factor 1 alpha (HIF-1α) and HIF-2α in hypoxic gene regulation. Mol Cell Biol 23:9361-9374, 2003
14. Koukourakis MI, Bentzen SM, Giatromanolaki A, et al: Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J Clin Oncol 24:727-735, 2006
15. Cao Y, Sonveaux P, Liu S, et al: Systemic overexpression of angiopoietin-2 promotes tumor microvessel regression and inhibits angiogenesis and tumor growth. Cancer Res 67:3835-3844, 2007
16. McLendon RE, Wikstrand CJ, Matthews MR, et al: Glioma-associated antigen expression in oligodendroglial neoplasms: Tenascin and epidermal growth factor receptor. J Histochem Cytochem 48:1103-1110, 2000
17. Choe G, Horvath S, Cloughesy TF, et al: Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res 63:2742-2746, 2003
18. Macdonald DR, Cascino TL, Schold SC, et al: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280, 1990
19. Cairncross JG, Ueki K, Zlatescu MC, et al: Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 90:1473-1479, 1998
20. Hegi ME, Diserens AC, Gorlia T, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003, 2005
21. Mischel PS, Cloughesy T: Using molecular information to guide brain tumor therapy. Nat Clin Pract Neurol 2:232-233, 2006
22. Prados MD, Lamborn KR, Chang S, et al: Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neuro Oncol 8:67-78, 2006
23. Batchelor TT, Sorensen AG, di Tomaso E, et al: AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11:83-95, 2007
24. Friedman HS, Petros WP, Friedman AH, et al: Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol 17:1516-1525, 1999
25. Batchelor TT, Gilbert MR, Supko JG, et al: Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: Final report of NABTT 97-11. Neuro Oncol 6:21-27, 2004
26. Prados MD, Lamborn K, Yung WK, et al: A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium study. Neuro Oncol 8:189-193, 2006
27. Pope WB, Lai A, Nghiemphu P, et al: MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 66:1258-1260, 2006
28. Jubb AM, Hurwitz HI, Bai W, et al: Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol 24:217-227, 2006
29. Swietach P, Vaughan-Jones RD, Harris AL: Regulation of tumor pH and the role of carbonic anhydrase 9. Cancer Metastasis Rev 26:299-310, 2007
30. Atkins M, Regan M, McDermott D, et al: Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 11:3714-3721, 2005
31. Wong ET, Hess KR, Gleason MJ, et al: Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17:2572-2578, 1999
32. Carson KA, Grossman SA, Fisher JD, et al: Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the New Approaches to Brain Tumor Therapy CNS Consortium phase I and II clinical trials. J Clin Oncol 25:2601-2606, 2007
33. Serganova I, Humm J, Ling C, et al: Tumor hypoxia imaging. Clin Cancer Res 12:5260-5264, 2006